Gilead's newest acquisition: a liver disease drug with $1B in peak sales potential
Gilead’s acquisition of CymaBay Therapeutics underscores the company’s historic success in liver diseases and could bring in $1 billion in peak annual sales.
Gilead announced Monday that it will pay cash to buy CymaBay for $4.3 billion, at $32.50 a share.
CymaBay is developing seladelpar as a second-line treatment for primary biliary cholangitis, a rare, chronic and progressive disease. The drug, which showed off positive Phase III results in September, has a PDUFA date in mid-August.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.